Available treatment options for hyperuricemic patients

Mihai-Emil GHERGHINA, Ileana PERIDE, Mirela TIGLIS, Tiberiu Paul NEAGU, Andrei NICULAE, Ionel Alexandru CHECHERITA

1 Clinical Department No. 3, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
2 Clinical Department No. 14, “Carol Davila” University of Medicine and Pharmacy, Bucharest Romania
3 Clinical Department No. 11, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

ABSTRACT

The negative impact of an elevated serum uric acid on the onset and/or progression of different diseases is well known. During the last decade, new forms of therapies were developed, with beneficial results on correcting hyperuricemia, but also with potential side effects that should not be overlooked as most of the hyperuricemic patients are presenting concomitant comorbidities that could influence the decision in prescribing a specific lowering serum uric acid drug. The review will describe recent treatment options, part of them available also in our country.

Keywords: hyperuricemia, xanthine oxidase inhibitors, uricosurics, adverse effects

INTRODUCTION

Hyperuricemia condition, physicochemical defined as an elevation of serum uric acid level more than 7 mg/dl, represents an important health problem that can contribute to the development and/or progression of different pathologies, such as chronic kidney disease, gout, insulin resistance syndrome, cardiovascular diseases, including hypertension etc. [1,2]. Furthermore, different studies concluded a significant increase of uricemia especially in high-income and economically developing countries, with a similar distribution between genders (21.2% in men, 21.6% in women, respectively) [3-6].

Considering all these aspects, including different factors that could contribute to the augmentation of serum uric acid (i.e. age, especially above 60 years old, kidney function, exogenous causes, mainly dietary habits, such as increased alcohol, processed food consumption etc.), there is a worldwide keen interest in determining the most suitable treatment approach in lowering elevated concentration of serum uric acid [7,8].

URIC ACID NORMAL PRODUCTION. POTENTIAL RISK FACTORS INCriminated IN THE DEVELOPMENT OF HYPERURICEMIA

In order to comprehend the adequate drug therapy that could be considered as appropriate for this group of patients, it is important to understand the normal mechanisms of uric acid production, determined by the purine metabolism (Figure 1) [2,3].
Considering the normal physiological pathway of uric acid production, there are several potential causes that could lead to the development of hyperuricemia, risk factors that are important to be acknowledged in order to apply the best treatment strategy in these patients (Table 1) [3,9-17].

Once the therapy management in lowering serum uric acid quantity is initiated, the physician should carefully monitor the serum level of uric acid as, nowadays, several studies reported a correlation between serum uric acid values below the normal range and the negative impact on different pathologies, such as multiple sclerosis, neoplasia, Parkinson’s disease etc. [2,18-22].

**AVAILABLE DRUG. TREATMENT STRATEGIES**

Depending on their mechanism and site of action in lowering serum uric acid, the available drugs could be classified into reducing uric acid production through xanthine oxidase inhibition (i.e. Allopurinol, Febuxostat, Topiroxostat); inhibiting uric acid reabsorption (i.e. Benzbromarone, Probencid, Lesinurad, Arhofenate, Verinurad); increasing uric acid removal (i.e. Pegloticase); other drugs with potential uricosuric effect (i.e. sodium-glucose co-transporter 2 inhibitors, fenofibrate, losartan, vitamin C, salicylate/salicylic acid and indomethacin), but further extensive clinical trials are required to validate their use in the treatment of hyperuricemia [3,7].

**Allopurinol**

Allopurinol represents the most common drug used in patients presenting hyperuricemia, being administered orally or parenterally. It is metabolized to alloxanthine that inhibits the enzyme xanthine oxidase. Allopurinol is metabolized through the liver and has a biological half-life of 2-3 hours. The main adverse / side effects reported were: gastrointestinal complaints, skin rash, eosinophilia, intestinal nephritis, hepatitis. The daily dose can vary between 100 and 600 mg, but several studies reported that a dose lower than 300 mg/
day could be effective in decreasing the risk of cardiovascular events [7,23] and in addition, high doses of Allopurinol are contraindicated in patients diagnosed with chronic kidney disease, especially if they are under treatment with thiazides [7,24]. Allopurinol could interact also with other drugs, such as didanosine (an antiretroviral; major contraindication) [7,25], azathioprine (requiring lowering the dose of the immunosuppressive) etc. [7].

**Febuxostat**

Febuxostat is another xanthine oxidase inhibitor that is also metabolized through the liver, and could associate the following adverse / side effects: muscle pain, gastrointestinal complaints, increase of liver enzymes [7]. Its biological half-life is of 5-8 hours, and the daily dose is between 80 and 120 mg [7]. It is considered superior to Allopurinol as it presents a concomitant anti-inflammatory effect (on the endothelium) [7,26,27] and the possibility to decrease serum uric acid with lower doses (40 mg/day Febuxostat versus 300 mg/day Allopurinol) [7]. Nevertheless, recent studies highlighted the potential link between Febuxostat and the increase of cardiovascular mortality [7, 28], and, therefore, Allopurinol is recommended as first-line therapy in hyperuricemia [7, 29]. Regarding patients diagnosed with chronic kidney disease, there are trials that supported the use of Febuxostat, presenting a nephroprotective effect comparing with Allopurinol [7,30-32].

**Topiroxostat**

Topiroxostat, another xanthine oxidase inhibitor, hepatically metabolized, with a biological half-life between 4.5 and 7.5 hours, and with possible fewer adverse / side effects (polyarthritis, increase of hepatic enzymes), is considered to be safely used in chronic disease patients, undergoing or not hemodialysis – usual daily dose of 160 mg [7,33,34].

**Probenecid**

Probenecid represents another uricosuric that inhibits uric acid reabsorption. It has a biological half-life of 4-12 hours and the recorded adverse / side effects include gastrointestinal disorders, skin rash. The main concern regarding Probenecid administration is the renal toxicity (most of its metabolites are renal excreted), therefore, due to the lack of data related to drug safety in patients with a glomerular filtration rate below 50 ml/min/1.73 m$^2$, it should be avoided in this group of patients [7].

**Other uricosurics that inhibit uric acid reabsorption**

Benzbromarone has a biological half-life of 4-17 hours [7]. Due to its important hepatic toxic effect, it was withdrawn from several countries [7].

Lesinurad has a biological half-life between 9 and 10 hours, and can present the following adverse / side effects: nephrotoxicity, increase risk of cardiovascular mortality [7]. Therefore, it is contraindicated in patients with a serum creatinine level over 4 mg/dl, uncontrolled hypertension, recent myocardial infarction or diagnosed with heart failure NYHA class III / IV [7,35].

Arhalofenate presents a biological half-life of almost 50 hours, and could be associated with different adverse effects: increase in creatine kinase, kidney stones, angioedema, peripheral neuropathy [7]. It is considered the first choice of treatment for gout flares [7].

Verinurad represents an URAT1 inhibitor, currently under investigation, but with promising results in treating gout and asymptomatic hyperuricemia. It was correlated with the development and progression of renal impairment.

**Pegloticase**

Pegloticase is an intravenous uricosuric that determines an increase of uric acid removal [7]. It has a biological half-life time for 6.4-13.8 days, and its main adverse effects are: gastrointestinal complaints, dyspnea, headache, urticaria, acute gout attacks, decrease of blood pressure, methemoglobinemia etc. [7]. It is contraindicated in patients diagnosed with glucose-6-phosphate dehydrogenase deficiency [7,36] and due to development of anti-drug antibody during the treatment, concomitant immunosuppressive therapy should be considered [7,37].

**CONCLUSIONS**

Hyperuricemia, due to its multiple implications, is considered an important risk factor in the development and/or progression of different pathologies (i.e. renal, metabolic, cardiovascular diseases), should be effectively treated, but nevertheless, important aspects should be emphasized, such as the adequate type of drug elected in lowering serum uric acid, considering its potential adverse effects, the patients’ comorbidities, and, in addition, an optimal assessment of serum uric acid concentration as a significant decrease could be correlated with several neurological or neoplastic diseases’ poor outcome.
REFERENCES

1. Mount DB. Asymptomatic hyperuricemia. UpToDate, 2020.

2. Kutzing MK, Firestein BL. Altered uric acid levels and disease states. J Pharmacol Exp Ther. 2008;324(1):1-7.

3. Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricaemia. Am J Transl Res. 2020;12(7):3167-3181.

4. Singh G, Lingala B, Mittal A. Gout and hyperuricaemia in the USA: prevalence and trends. Rheumatology (Oxford). 2019;58(12):2177-2180.

5. Liu H, Zhang XM, Wang YL, Liu BC. Prevalence of hyperuricaemia among Chinese adults: a national cross-sectional survey using multistage, stratified sampling. J Nephrol. 2014;27(6):653-658.

6. Roman YM. The Daniel K. Inouye College of Pharmacy Scripts: Perspectives on the Epidemiology of Gout and Hyperuricaemia. Hawaii J Med Public Health. 2019;78(2):71-76.

7. Cicero AFG, Fogacci F, Kuwabara M, Borghi C. Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update. Medicina (Kaunas). 2021;57(1):58.

8. Katski N, Karagiannis A, Athyros VG, Mikhailidis DP. Hyperuricaemia: more than just a cause of gout? J Cardiovasc Med (Hagerstown). 2013;14(6):397-402.

9. Robinson PC. Gout - An update of aetiology, genetics, co-morbidities and management. Maturitas. 2018;118:67-73.

10. Wang H, Zhang H, Sun L, Guo W. Roles of uric acid and its levels and disease states. J Pharmacol Exp Ther. 2020;372(6):879-895.

11. Roddy E, Choi HK. Epidemiology of gout. Rheum Dis Clin North Am. 2014;40(2):155-175.

12. Ni Q, Lu X, Chen C, Du H, Zhang R. Risk factors for the development of hyperuricemia: A STROBE-compliant cross-sectional and longitudinal study. Medicine (Baltimore). 2019;88(42):e17597.

13. Chaudhury NS, Bridges SL Jr, Saag KG, Rahn EJ, Curtis JR, Gaffo A, et al. Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort Study. Hypertension. 2020;75(1):246-256.

14. Steiger S, Ma Q, Anders HJ. The case for evidence-based medicine for the association between hyperuricaemia and CKD. Nat Rev Nephrol. 2020;16(7):422.

15. Sato Y, Feig DI, Stack AG, Kang DH, Lanaspa MA, Eijaz AA, Sánchez-Lozada LG, Kuwabara M, Borghi C, Johnson RJ. The case for uric acid-lowering treatment in patients with hyperuricemia and CKD. Nat Rev Nephrol. 2019;15(12):767-775.

16. Dalbeth N, Choi HK, Joosten LAB, Khanha PP, Matsuo H, Perez-Ruiz F, Stamp LK. Gout. Nat Rev Dis Primers. 2019;5(1):69.

17. Benn CL, Dua P, Gurrell R, Loudon P, Pike A, Storer RJ, Vangjeli C. Physiology of Hyperuricemia and Urate-Lowering Treatments. Front Med (Lausanne). 2018;5:160.

18. Church WH, Ward VL. Uric acid is reduced in the substantia nigra in Parkinson’s disease: effect on dopamine oxidation. Brain Res Bull. 1994;33(4):419-425.

19. Toncev G, Milicic B, Toncev S, Samardzic G. Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neuro. 2002;9(3):221-226.

20. Knapp CM, Constantinescu CS, Tan JH, McLean R, Cherrymann GR, Gottlob I. Serum uric acid levels in optic neuritis. Mult Scler. 2004;10(3):278-280.

21. de la ULM, Koudstaal PJ, Hofman A, Breteler MM. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol. 2005;58(5):797-800.

22. Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ, Kim JJ, Lee SJ, Lee C, Paik IH, Lee CU. Decreased plasma antioxidants in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 2006;21(4):344-348.

23. Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, Dalbeth N. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64(8):2529-2536.

24. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134-4139.

25. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultAndAdolescentGL.pdf.

26. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540-1548.

27. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018;378(13):1200-1210.

28. FitzGerald JD, Dalbeth N, Mikuls T, Briganddell-Petersen R, Guyatt G, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020;72(6):879-895.

29. Borghi C, Perez-Ruiz F. Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2016;20(5):983-992.

30. Kim S, Kim HJ, Ahn HS, Oh SW, Han KH, Um TH, Cho CR, Han SY. Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis. Kidney Res Clin Pract. 2017;36(3):274-281.

31. Baek CH, Kim H, Yang WS, Han DJ, Park SK. Efficacy and Safety of Febuxostat in Kidney Transplant Patients. Exp Clin Transplant. 2018;16(4):401-406.

32. Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimoto S, Yamamoto T, Hara S. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuremic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol. 2014;18(6):876-884.

33. Nagaoka Y, Tanaka Y, Yoshimoto H, Suzuki R, Ryu K, Ueda M, Akiyama M, Nagai M, Miyaoka Y, Kanda E, Iwai S, Nagaoka M, Kanno Y. The effect of small dose of topiroxostat on serum uric acid in patients receiving hemodialysis. Hemodial Int. 2018;22(3):388-393.

34. Bardin T, Richette P. Novel uricosurics. Rheumatology (Oxford). 2018; 57(suppl_1):i42-i46.

35. Roberts RL, Stamp LK. Pharmacogenetic considerations in the treatment of gout. Pharmacogenomics. 2015;16(6):619-629.

36. Botson JK, Tesser JRP, Bennett R, Kenney HM, Peloso PM, Obermeyer K, LaMoreaux B, Weinblatt ME, Peterson J. Pegloticase in Patients With Uncontrolled Gout: A Multicenter, Open-Label Study (MIIRROR). J Rheumatol. 2021; 48(5):767-774.